Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Frontage Holdings Corp. ( (HK:1521) ) is now available.
Frontage Holdings reported broadly flat 2025 revenue of US$256.7 million, but significantly improved profitability, with EBITDA rising 8.0% and net profit jumping to US$6.8 million from US$0.6 million a year earlier. Adjusted net profit increased 18.9% to US$15.7 million, reflecting better operating efficiency and margin expansion, although the board decided not to recommend a final dividend for the year, signaling a continued focus on reinvestment and balance sheet strength over near-term cash returns to shareholders.
The most recent analyst rating on (HK:1521) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Frontage Holdings Corp. stock, see the HK:1521 Stock Forecast page.
More about Frontage Holdings Corp.
Frontage Holdings Corporation is a contract research organization that provides laboratory and related services to the pharmaceutical and biotechnology industries. The group focuses on outsourced R&D support, offering specialized scientific and analytical capabilities to global drug developers seeking efficient and compliant development pathways.
Average Trading Volume: 186,171
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.32B
For an in-depth examination of 1521 stock, go to TipRanks’ Overview page.